{"prompt": "['Nitrite benefits to mediate fatigability in older HFpEF patients', 'Daniel E. Forman, MD', 'Principal Investigator', 'Professor of Medicine', 'University of Pittsburgh Medical Center', 'University of Pittsburgh School of Medicine', 'Chair, Geriatric Cardiology Section', 'NCT Number: 02918552', 'Version 10.0', 'April 9, 2018']['Oral Nitrite for fatigability in HFpEF', 'Sponsor: Mark T. Gladwin, MD', 'TABLE OF CONTENTS', 'PROTOCOL SYNOPSIS', '3-9', '1.', 'STUDY OBJECTIVE, SPECIFIC AIMS, BACKGROUND AND SIGNIFICANCE', '9-13', '1.1 OBJECTIVE', '9', '1.2 SPECIFIC AIMS', '9', '1.3 BACKGROUND', '9-10', '1.4 SIGNIFICANCE', '10-13', '2.', 'RESEARCH DESIGN AND METHODS', '13-35', '2.1 CLASSIFICATION AND METHODOLOGICAL DESIGN', '13', '2.2 DETAILED DESCRIPTION OF STUDY DESIGN', '13-23', '2.2.1 TABLE OF STUDY VISITS AND ASSESSMENTS', '25', '2.3 STUDY DRUGS', '26-32', '2.4 STUDY ENDPOINTS', '32', '2.5 STATISTICAL ANALYSIS', '32-34', '3.', 'HUMAN SUBJECTS', '34-36', '3.1 SUBJECT POPULATION', '34', '3.2 INCLUSION CRITERIA', '35-36', '3.3 EXCLUSION CRITERIA', '36', '4.', 'IRB APPROVAL AND FDA AMENDMENTS', '36-37', '5.', 'RECRUITMENT AND INFORMED CONSENT PROCEDURES', '37-38', '5.1 RECRUITMENT METHODS', '37-38', '5.2 INFORMED CONSENT PROCEDURES', '39', '6.', 'POTENTIAL RISKS AND BENEFITS', '39-51', '6.1 POTENTIAL RISKS', '39-45', '6.2 ALTERNATIVE TREATMENTS', '45', '6.3 POTENTIAL BENEFITS', '46', '6.4 DATA SAFETY MONITORING', '46-51', '6.5 RISK MANAGEMENT PROCEDURES', '49-51', '7.', 'COSTS AND PAYMENTS', '53', '7.1 COSTS', '53', '7.2 PAYMENTS', '53', '8.', 'QUALIFICATIONS AND SOURCE OF SUPPORT', '53-57', '8.1 QUALIFICATIONS OF THE INVESTIGATORS', '53-57', '8.2 SOURCE OF SUPPORT', '57', '9.', 'REFERENCES', '58-67', 'Version 10.0, April 9, 2018 2']['Oral Nitrite for fatigability in HFpEF', 'Sponsor: Mark T. Gladwin, MD', 'PROTOCOL SYNOPSIS', 'Protocol Title:', 'Nitrite benefits to mediate fatigability in older HFpEF patients', 'Protocol Number:', 'IND 115926', 'NCT Number:', '02918552', 'Version # and Date:', 'Version 10.0. / April 9, 2018', 'Clinical Phase:', 'Phase Il clinical investigation', 'Investigational Drugs:', 'Nitrogen 14 Sodium Nitrite (14N Sodium Nitrite)', 'Trial Site:', 'University of Pittsburgh Single-Center Randomized Trial', 'IND Sponsor:', 'Mark T. Gladwin, MD', 'Professor & Chairman of the Department of Medicine', 'Director, Pittsburgh Heart, Lung, Blood and', 'Vascular Medicine Institute', 'Department of Medicine', '1218 Scaife Hall', '3550 Terrace St, Pittsburgh, PA 15261', '412-648-9636', 'Investigator:', 'Daniel E. Forman, MD', 'Professor of Medicine', 'Chair, Geriatric Cardiology Section', 'University of Pittsburgh', '3471 Fifth Avenue, Suite 500', 'Pittsburgh, PA 15213', 'Sub-Investigators:', 'Jessica Bon Field, MD', 'Mark T. Gladwin, MD', 'Nancy Glynn, PhD', 'Bret Goodpaster, PhD', 'John Gorcsan, MD', 'Hoby Hetherington, PhD, MS', 'Gavin Hickey, MD', 'Kara Hughan, MD, MHSc', 'Theodore Huppert, PhD', 'Manisha Jhamb, MD, MPH', 'Andrea Levine, MD', 'Anne Newman, MD, MPH', 'Subashan Perera, PhD', 'Michael Risbano, MD', 'Adam Santanasto, MPH, PhD', 'Sruti Shiva, PhD', 'Marc Simon, MD, MS', 'Frederico Toledo, MD', 'Version 10.0, April 9, 2018 3']\n\n###\n\n", "completion": "END"}